Oxurion Halts Acquisition of a French CRO, Shifts Focus to International Expansion
Belgian biotech company Oxurion has ended discussions on acquiring a French Contract Research Organization (CRO), previously announced in October 2025. The company is now prioritizing the acquisition of an international CRO operating across Europe, North Africa, and the Middle East.
Termination of Negotiations on the French Project
Oxurion has decided to terminate discussions regarding the acquisition of a majority stake in a French CRO. This project was initially communicated on October 13, 2025, and extended on February 27, 2026. According to the statement, extensive due diligence conducted over the past months revealed that the necessary conditions to finalize the deal were not met. The biopharmaceutical group believes that the structure and robustness of the target's business plan do not align with its strategic and financial interests. This decision comes after several months of detailed evaluation.
Priority Given to the International Target
Oxurion is now redirecting its efforts towards acquiring a majority stake in an international CRO. This target operates in Europe, North Africa, and the Middle East, as announced on March 19, 2026. The group is continuing exclusive discussions regarding this acquisition. Oxurion aims to build an integrated platform in clinical development, combining multi-country operational expertise and advanced solutions in clinical data sciences.
Company Overview
Oxurion is a Belgian biotech based in Leuven, specializing in acquiring majority stakes in European pharmaceutical subcontractors. The group aims to construct an integrated network of providers serving the healthcare sector.
